Printer Friendly

Gloucester Pharmaceuticals Initiates Phase I/II Clinical Study in Pancreatic and Other Advanced Solid Tumors; Combination Trial Will Investigate Romidepsin (Depsipeptide) in Combination with Gemcitabine.

CAMBRIDGE, Mass. -- Gloucester Pharmaceuticals, Inc., a privately held cancer therapeutics development company, announced today that it has enrolled and treated the first patient in a phase I/II clinical study of romidepsin in combination with gemcitabine to treat pancreatic cancer and other solid tumors.

The Company anticipates enrolling approximately 30 patients in an open-label, single-arm study. Patients will receive romidepsin and gemcitabine at various doses in order to establish the most appropriate dose for each drug in this combination regimen. Once the appropriate dose of each drug is determined, additional patients will be treated at that dosing regimen. The endpoints for this trial include both safety and objective response to therapy.

"This clinical trial will expand on recent preclinical data suggesting that romidepsin may enhance the activity of gemcitabine," commented Howard Burris, M.D., of the Sarah Cannon Research Institute and principal investigator of the study. "Gemcitabine is already approved for the treatment of pancreatic cancer and we hope to find that using it in combination with romidepsin may improve patient outcomes. Despite recent advances, pancreatic cancer is still a leading cause of cancer death in the United States and innovative new treatments are clearly needed," he concluded.

About Romidepsin (Depsipeptide)

In July 2006 the International Nonproprietary Names (INN) body of the World Health Organization (WHO) and the United States Adopted Names (USAN) Council approved the nonproprietary (generic) name romidepsin for depsipeptide (FK228). Romidepsin is a novel agent in a new class of anti-cancer drugs known as histone deacetylase inhibitors. The Company is conducting a pivotal study of romidepsin for patients with cutaneous T-cell lymphoma (CTCL). Interim data for this trial, recently presented at the American Society of Clinical Oncology meeting, included 40 patients enrolled and 28 evaluable patients. The overall response rate was 36% (10/28) with 7% of patients achieving a complete response. The most common adverse events seen in this trial were nausea (52%), fatigue (33%) and vomiting (26%). This study is currently accruing patients. Romidepsin has received both Fast Track and Orphan Drug Designation by the Food and Drug Administration (FDA), and Orphan Drug Designation from the European Agency for the Evaluation of Medicinal Products (EMEA). Romidepsin is also in clinical trials for a variety of other hematologic malignancies and solid tumors including peripheral T-cell lymphoma, hormone refractory prostate cancer and multiple myeloma. These trials and others are being conducted by the Company or the National Cancer institute (NCI), under a Cooperative Research and Development Agreement (CRADA) with the Company.

About Gloucester Pharmaceuticals, Inc.

Gloucester Pharmaceuticals, Inc. is a privately held, venture-backed company that develops and commercializes innovative products for the treatment of cancer patients. Gloucester is headquartered in Cambridge, MA. For more information on Gloucester and our clinical development program visit our website at www.gloucesterpharma.com or call 888-GPI-CTCL (888-474-2825).

Information on Gloucester's clinical trials can also be found at:

www.clinicaltrials.gov/ct/show/NCT00106431 regarding cutaneous T-cell lymphoma

www.clinicaltrials.gov/ct/show/NCT00106418 regarding prostate cancer
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Sep 12, 2006
Words:495
Previous Article:Glu Research Finds Consumers Still in the Dark About Mobile Games; Research Demonstrates Industry Too Focused on Carrier Decks to Reach Gamers;...
Next Article:BancTec Helps CFOs Reduce Cost Per Invoice With New Accounts Payable Solutions and Services; New BancTec AP Master(TM) Offerings Increase Process...
Topics:


Related Articles
LORUS' VIRULIZIN EFFECTIVE AGAINST PANCREATIC TUMORS.
Gloucester Pharmaceuticals Reports on Phase 2 Clinical Study Presented at the American Society of Clinical Oncology 2006 Prostate Cancer Symposium;...
Gloucester Pharmaceuticals Reports Clinically Significant Responses in Interim Analysis of Pivotal Trial for Cutaneous T-Cell Lymphoma at the 2006...
Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for Peripheral T-Cell Lymphoma at the 2006 American Society of...
OSI Pharmaceuticals Announces European Regulatory Approval of Tarceva(R) for Treatment of Patients with Pancreatic Cancer.
Gloucester Pharmaceuticals Receives Special Protocol Assessment for Pivotal Phase II Trial of Romidepsin in Patients with Peripheral T-Cell Lymphoma.
Gloucester Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial in Patients with Multiple Myeloma.
Gloucester Pharmaceuticals' Development of Romidepsin for Cutaneous T-Cell Lymphoma Continues Following Planned Review by Data Safety Monitoring...
OSI Pharmaceuticals Announces Pivotal Phase III Tarceva(R) Study Published in the Journal of Clinical Oncology Showed Survival Improvement in...
New Data Show Pfizer's Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters